Skip to main content

Clinical Trial Results

Search

Aspirin in 2022: A New Aspirin for a New Chapter

Dr. Neha J. Pagidipati, Dr. Jacqueline E. Tamis-Holland, Dr. Dominick J. Angiolillo and Dr. C. Michael Gibson Discuss: Aspirin in 2022: A New Aspirin for a New Chapter – Clarifying Aspirin Therapy in Secondary Prevention and DAPT for the Practicing Clinician: A Town Hall

Full Town Hall

Dr. Dominick J. Angiolillo discusses the Latest FDA approved Aspirin- PL-ASA

Dr. Neha J. Pagidipati discusses Apririn Use in Secondary Prevention-Patients with Diabetes and/or Obesity

Dr. Jacqueline E. Tamis-Holland discusses Guideline Recommendations for Aspirin Use after Coronary Revascularization- DAPT-SAPT what do the New Guidelines Tell Us

Loader Loading…
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

Download [12.08 MB]

Disclosures: